Avicena Group, Inc. to Present at 4th Annual Biotechnology Industry Organization (BIO) InvestorForum Conference Expansion of Drug Pipeline and Advancement of Clinical Programs
Published: Oct 09, 2007
PALO ALTO, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Avicena Group, Inc. , a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders, announced today that it will be a presenting company at the 4th Annual BIO InvestorForum Conference to be held October 9-11, 2007 at the Palace Hotel of San Francisco. The company's chief executive officer, Belinda Tsao-Nivaggioli, Ph.D., will present an overview of the company and its clinical programs, including an update on activities to build its drug pipeline and investigate new delivery vehicles to enhance the bioavailability of its lead drug candidates. Dr. Tsao-Nivaggioli will be presenting on Thursday, October 11 at 10:30 a.m. (EDT) in the Twin Peaks North room. For more information on this event please visit: http://www.investorforum.bio.org/.
To participate in a live audio and visual webcast of Dr. Tsao-Nivaggioli's presentation please log onto Avicena's corporate website at http://www.avicenagroup.com at least fifteen minutes prior to the start of the presentation to download any necessary materials. An archive of this event will be available in the investor relations section of the website for 30 days.
Avicena Group, Inc. is a Palo Alto, California based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). Near term, the company plans to initiate a confirmatory Phase III trial in ALS and a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trail in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.
firstname.lastname@example.org@theruthgroup.com or email@example.com
CONTACT: Sara Ephraim (investors), +1-646-536-7002,
firstname.lastname@example.org, or, media, Janine McCargo, +1-646-536-7033,
email@example.com, or Jason Rando, +1-646-536-7025,
firstname.lastname@example.org, all of The Ruth Group, for Avicena Group, Inc.
Web site: http://www.avicenagroup.com/